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KEY POINTS
 Feline chronic gingivostomatitis seems to be a manifestation of an aberrant immune
response to chronic antigenic stimulation.
 Multicat environments play an important role and are associated with this multifactorial
disease.
 The current standard of care involves dental extractions of at least all premolar and molar
teeth, with or without medical management, rather than medical therapy alone.
 Future regenerative therapies, currently in development, show promise for management
of feline chronic gingivostomatitis.INTRODUCTION
Feline chronic gingivostomatitis (FCGS) is a severe, immune-mediated, oral mucosal
inflammatory disease of cats. The typical location of the ulcerative and/or proliferative
inflammatory lesions is lateral to the palatoglossal folds, previously referred to as the
fauces.1–3 Clinically, a proliferative and ulcerative phenotype of the disease can be
observed (Fig. 1). Occasionally, the proliferative form of the disease is so severe as
to prevent retraction of the tongue (Fig. 2). Although FCGS is a familiar condition
encountered in veterinary practice, with a reported prevalence ranging from 0.7% to
12.0%,4–6 there is much confusion regarding the cause and subsequent treatment
of the disease.6,7 This article reviews the current knowledge on the etiopathogenesis
of FCGS and describes the leading treatment modalities.
ETIOPATHOGENESIS
The cause of FCGS remains elusive despite extensive investigations. A multitude of
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Fig. 1. The hallmark of FCGS is inflammation in the caudal oral cavity in the area lateral to
the palatoglossal folds. Ulcerative (A) and proliferative (B) phenotypes can be observed.
Lee et al2including infectious pathogens such as feline calicivirus (FCV), feline herpesvirus
(FHV-1), feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), and various
bacteria, as well as noninfectious factors such as dental disease, environmental
stress, and hypersensitivity.8–23 Little or no new information has been forthcoming
in this regard.
Systemic and Local Consequences of Feline Chronic Gingivostomatitis
The chronic inflammatory nature of the disease is suggested by the predominant pres-
ence of lymphocytes and plasma cells in affected oral tissues, with fewer neutrophils,
Mott cells, and mast cells.24,25 Immunohistochemical staining has revealed the infiltra-
tion of cluster of differentiation (CD) 31 T lymphocytes within the epithelium and sub-
epithelial stroma, and restriction of CD201 B lymphocytes mainly to the subepithelial
stroma (Fig. 3).26,27
Increased levels of CD81 (cytotoxic) T cells, compared with CD41 (helper) T cells,
have been detected locally as well as in the systemic circulation, suggesting that the
inflammatory response seen in FCGS is a cytotoxic cell-mediated immune response to
antigenic stimulation likely from intracellular pathogens such as viruses.7,26,27Fig. 2. Occasionally, the proliferative inflammation can be so severe as to prevent the
tongue from retracting into its normal and functional position.
Fig. 3. On histology, the healthy oral mucosa of cats is composed of squamous epithelium
with a rare presence of inflammatory cells (A). However, in cats affected by FCGS, ulceration
of the squamous epithelium is observed with profound inflammatory infiltration comprising
mostly granulocytes, lymphocytes, plasma cells, and mast cells (B) (hematoxylin-eosin [H&E]
staining, original magnification 10). Immunohistochemistry of FCGS mucosal inflammation
indicates that most of the T lymphocytes (CD3 cells) are present in the epithelium (C) and
most of the B lymphocytes (CD20 cells) are present in the submucosa (D) (original magnifica-
tion 10 ).
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with FCGS, with a normal percentage of CD41 T cells and an increased percentage of
CD81 T cells in circulation.26,27 In humans, a low CD4/CD8 ratio is typically associated
with immune dysfunction, immune senescence, and chronic inflammation, and is seen
in immunodeficiency or autoimmune diseases such as human immunodeficiency vi-
rus/acquired immunodeficiency syndrome, systemic lupus erythematosus, and
Lee et al4neoplasia, supporting the notion that an aberrant immune response is also involved in
FCGS.28 Interestingly, systemic administration of autologous mesenchymal stem cells
(MSCs) in cats has been shown to normalize the CD4/CD8 ratio because of normali-
zation of the percentage of CD81 T cells, reinforcing the finding that CD81 T cells play
a noteworthy role in the pathophysiology of FCGS.27
Potential Viral Causes
FCV, FHV-1, FIV, and FeLV have been implicated in FCGS. Demonstration of causal
relationships have not been successful, but, of these agents, FCV seems to have
the most consistent evidence of being associated with FCGS.9,12,18–20,29–31 A recent
study found the incidence of FCV to be significantly higher in cats with FCGS (60%)
compared with control cats (24%) as well as cats with feline resorptive lesions
(23%).32 Regardless, well-known risk factors for these viruses include free-roaming
behavior and living in multicat environments such as shelters, shared households,
and breeding catteries. This finding is worth exploring given that the etiopathogenesis
of FCGS is likely multifactorial.
Environmental Stressors
A recent study investigated the association of multicat environments and outdoor ac-
cess with the prevalence of FCGS.33 It was revealed that the prevalence of FCGS was
higher in multicat than single-cat households, and that each additional cat in the
household increased the odds of FCGS by more than 70%. Association between out-
door access and FCGS was lacking, suggesting that factors relating to multicat envi-
ronments may be necessary in addition to an infectious cause to trigger the
development of FCGS. Examples mentioned in the article include the favoring of
high rates of viral evolution and cyclic reinfections in susceptible individuals caused
by chronic exposure to viruses shed by chronic carriers in multicat environments,
as well as the stress of living in such environments.33,34
Feline Chronic Gingivostomatitis and Periodontitis
The association between FCGS and periodontitis has been proved in a retrospective
case-control study where full-mouth dental radiographs of 101 cats with FCGS and
101 control cats with other oral diseases were evaluated.10 This study revealed that
not only do cats with FCGS have generalized, advanced periodontitis but they are
also significantly more likely to have external inflammatory root resorption. The find-
ings underscore that dental radiography plays an essential role in the diagnosis and
evaluation of cats with FCGS, and that the treatment of associated periodontitis, likely
contributing to persistent oral inflammation, is integral in the treatment of FCGS.
Bacterial Burden in Feline Chronic Gingivostomatitis
Bacterial organisms are thought to play a role in the pathogenesis of FCGS. The oral
microbial diversity is less in cats with FCGS than in healthy cats, with the predominant
species being Pasteurella multocida subsp. multocida.17 Consistent with previous
studies, a recent study found higher abundance of gram-negative and anaerobic bac-
teria in FCGS and periodontitis.21 The phylum Bacteroidetes and the genus Peptos-
treptococcus were more abundant in cats with FCGS than in healthy cats and cats
with periodontitis. The findings suggest that Filifactor and Peptostreptococcus may
play a role in periodontitis of FCGS. In contrast with the study mentioned previously,
this study found higher bacterial diversity in the oral microbiota of cats with FCGS and
periodontitis, suggesting a possible role of bacterial biofilms in the pathophysiology
both of these oral diseases.
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It has recently been found that esophagitis seems to occur concurrently with FCGS.35
In a controlled study involving 58 cats with FCGS, evidence of esophagitis was found
via esophagoscopy in 98% of cats with FCGS, compared with control cats. Interest-
ingly, none of the cats showed clinical signs of gastrointestinal disease. In addition,
microscopic evidence of inflammation and metaplasia was found on histopathologic
evaluation of grossly normal-appearing tissues. Endoscopic reexamination of 2 cats
that were treated for FCGS and no longer showed clinical signs of that disease also
showed macroscopic healing of esophagitis. One cat that had a relapse of FCGS
showed worsening of esophagitis despite appropriate treatment of esophagitis. Prior
medications, salivary and esophageal lumen pH, and chronicity of FCGS signs do not
correlate with the degree of esophagitis. The investigators speculated that the virulent
oral microbiota of cats with FCGS is transmitted to the esophagus via the saliva, where
the production of certain proinflammatory cytokines may contribute to the develop-
ment of esophagitis. In light of the findings of this study, diagnosis and treatment or
empiric treatment of esophagitis may be considered in cats affected by FCGS, espe-
cially considering that both diseases share some clinical signs (ie, ptyalism, nausea,
and inappetence).35
LEADING TREATMENT MODALITIES
In general, there are 2 approaches to the treatment of FCGS: surgical and medical.
However, on its own, medical treatment typically does not have favorable long-term
outcomes, making the current standard of care surgical intervention by means of
dental extractions with or without additional medical management. A wide range of
therapies has been suggested. However, only the most common and promising
(based on scientific evidence) modalities are discussed in this article.
Pain Management
Regardless of modality, all treatment options require adequate pain management.
Appropriate therapy depends on factors including comorbidities (eg, renal or hepatic
disease), concurrent medications being administered (eg, corticosteroids), patient
compliance, and the owner’s perception of oral pain. Typically, long-term pain man-
agement includes administration of opioids (eg, buprenorphine) complemented with
gabapentin. A recent randomized, prospective, blinded, controlled, crossover study
showed that buccal administration of buprenorphine had a significant effect on
reducing pain scores with low interindividual variations in plasma concentration in
cats with FCGS.36
Surgical Treatment
A few studies have shown that partial- (all premolar and molar teeth) or full-mouth
extraction provides the best long-term results.37–39 These studies report substantial
improvement or resolution of FCGS in approximately 70% to 80% of cats, with
approximately 20% to 30% of cats showing minimal or no improvement.
A retrospective case series involving 95 cats with FCGS treated with full-mouth or
partial-mouth extractions with concurrent medical management revealed that
28.4% of cats achieved complete resolution, 39% achieved substantial clinical
improvement, 26.3% had little improvement, and 6.3% had no improvement (refrac-
tory).37 Of the patients that achieved substantial improvement or complete resolution,
most (68.8%) required medical management with antimicrobial, antiinflammatory, or
analgesic medications for a finite period after the 2-week immediate postoperative
Lee et al6period. Those that had little or no improvement still required medical management at
the final recheck examination. A more recent study of 56 cats treated with dental ex-
tractions for FCGS showed that 51.8% achieved clinical cure or very significant
improvement within a median time of 38 days.38
Moreover, extent of dental extractions seems to have no impact on outcome.37,38
Therefore, partial-mouth extraction (plus other teeth that independently have indica-
tions for extraction, such as severe periodontitis, retained tooth roots, or resorptive le-
sions) as the first stage of treatment is the highest evidence-based recommendation. It
also has the advantages of reduction in anesthetic time, surgeon fatigue, and surgical
trauma. If there is no positive response within 1 to 4 months after partial-mouth extrac-
tion, full-mouth extractions may be pursued as the second stage of treatment based
on the findings of Druet and Hennet.37
Medical Management
As already mentioned, most cats with FCGS require medical management in addition
to surgical treatment, and some depend on lifelong medications. Because FCGS is an
immune-mediated inflammatory disease, the basis of medical therapy has been
immunosuppression or immunomodulation.5
Corticosteroids
Prednisolone is often used as a short-acting corticosteroid to control inflammation. In
a randomized, double-blinded, prospective, controlled study of calicivirus-positive
cats with FCGS refractory to dental extractions, it was used as the control (at 1 mg/
kg/d tapering over 3 weeks) to recombinant feline interferon omega.40 In the study,
23% of 11 cats that received treatment with prednisolone achieved substantial
improvement, of which 7% achieved clinical remission.40 Because of the potential
deleterious side-effects of long-term corticosteroid administration, it should only be
used as needed for symptomatic treatment, on a tapering course.
Recombinant feline interferon omega
Interferons (IFNs) are a group of signaling proteins that have the ability to interfere with
viral replication.40 Recombinant feline interferon omega (rFeIFN-u) is marketed for use
in canine parvovirus, FeLV, and FIV infections. Interferons also have antiviral activity
against FHV-1, FCV, and feline coronavirus.41 Oromucosal absorption of IFN has
been shown to stimulate immunomodulation via oropharyngeal lymphoid tissues,
whereas gastrointestinal absorption destroys the glycoprotein.42,43 In a controlled,
randomized, double-blinded study of oromucosal administration of rFeIFN-u for
3 months in 19 cats, substantial improvement was seen in 45%, of which 10%
achieved clinical remission. However, the results were not statistically significant be-
tween the 2 groups, implying that rFeIFN-u is at least as effective as short-term pred-
nisolone in the treatment of FCV-positive cats with refractory FCGS.40 A recent
controlled study showed that subcutaneous administration of rFeIFN-umay be effec-
tive for the treatment of FCGS in FCV-positive cats by inhibiting the replication of
FCV.44 Furthermore, a novel rFeIFN (rFeIFN-a15) has been produced via transgenic
silkworms that may carry a lower allergy risk, compared with the baculovirus expres-
sion system in silkworms by which the current form of rFeIFN-u is produced.45
Cyclosporine
Cyclosporine provides immunosuppressive effects primarily via inhibition of T-cell
activation by reducing interleukin-2 expression, a proinflammatory cytokine involved
in a positive feedback loop that increases T-cell numbers.46,47 It may also have inhib-
itory effects on B-cell reproduction.48 In a small retrospective case series that
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tions, 4 (50%) of the cats were reported to achieve clinical remission, whereas the rest
had partial to fairly good improvement.49 In a randomized, controlled, double-blinded,
prospective clinical trial where oral cyclosporine was administered to 9 cats that had
previously been treated with extractions, there was a statistical significance in the
number of cats experiencing significant clinical improvement over the 6-week study
period between the treatment group (77.8%) and the placebo group (14.3%).50
Long-term observation was continued in 11 cats, of which 5 (45.5%) were clinically
cured after receiving cyclosporine for 3 or more months.50
Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are fibroblastlike, multipotent stem cells that have
immunomodulatory effects through inhibition of T-cell proliferation, alteration of
B-cell function, downregulation of major histocompatibility complex II on antigen-
presenting cells, and inhibition of dendritic cell maturation.27,51–53 The efficacy of
both autologous and allogeneic, fresh, adipose-derived MSCs administered intrave-
nously has been studied in cats with refractory FCGS.26,27
Treatment with autologous adipose-derived MSCs in 7 cats resulted in a positive
response rate of 71.4% reflected by clinical remission in 42.8%, substantial improve-
ment in 28.6% of the cats, and no response in 28.6% of cats over a follow-up period of
6 to 24 months.27
A subsequent clinical trial examining the efficacy of allogeneic adipose-derivedMSCs
in 7 cats resulted in lower clinical efficacy with delayed clinical and histologic resolution
compared with autologous therapy.26 Of the 7 cats, 28.6% achieved clinical remission,
28.6% achieved substantial improvement, and 42.8% were nonresponders.26
Clinical trials involving MSCs are currently ongoing and have expanded into a multi-
center study to include control cats and to further investigate mechanism of action,
biomarkers, efficacy of therapy before surgical treatment, as well as efficacy in cats
with comorbidities52 (for more on MSC in feline medicine, see Webb’s article, “Stem
Cell Therapy and Cats: What Do We Know at this Time?” in this issue).
SUMMARY
Although the exact etiopathogenesis of FCGS remains unclear, it seems to be a mani-
festation of an inappropriate immune response to antigenic stimulation, potentially
potentiated or exacerbated by viral infection. Furthermore, environmental stressors
such as multicat environments seem to be an important contributing factor. The cur-
rent first line of treatment involves dental extractions of at least the premolar andmolar
teeth as opposed to medical therapy alone. Following surgical treatment, outcome
can be divided into approximate thirds for cats achieving remission, substantial
improvement, and little to no improvement. Most cats that undergo surgical treatment
need concurrent medical therapy for control of inflammation, some requiring lifelong
medical management. New modalities such as MSC therapy show promise. In addi-
tion, the importance of analgesic therapy cannot be overemphasized.
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